Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

Multibagger Stock: PTC Industries, an engineering component manufacturer, has experienced a remarkable surge in its share ...

This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...

PTC India Q2 Results Live : PTC India has declared its Q2 results on November 12, 2024, showcasing a mixed performance in key ...

In the corresponding quarter of the previous fiscal, PTC India posted a net profit of ₹130 crore, the company said in a ...